ICP
CRL icon

Ilex Capital Partners’s Charles River Laboratories CRL Stock Holding History

Ilex Capital Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.4M Sell
81,193
-115,287
-59% -$20.5M 0.38% 45
2026
Q1 		$33.9M Buy
+196,480
New +$36.4M 0.84% 38
2025
Q2 		– Sell
-10,585
Closed -$1.59M – 184
2025
Q1 		$1.59M Buy
+10,585
New +$1.77M 0.07% 142

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Ilex Capital Partners's CRL Position: Q2 2026 in Review

Ilex Capital Partners reduced its Charles River Laboratories (CRL) stake by 59% in Q2 2026, selling an estimated $20.5M and leaving 81,193 shares worth $18.4M. The position accounts for 0.38% of the portfolio, ranked #45.

Ilex Capital Partners first reported a position in CRL in Q1 2025 and has held it in 3 quarters since. The position peaked at $33.9M in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Ilex Capital Partners held 81,193 shares of Charles River Laboratories worth $18.4M as of Q2 2026.
  • Ilex Capital Partners sold 115,287 Charles River Laboratories shares in Q2 2026, an estimated $20.5M.
  • Charles River Laboratories made up 0.38% of Ilex Capital Partners's portfolio in Q2 2026, its #45 holding.
  • Ilex Capital Partners first reported a position in Charles River Laboratories in Q1 2025 and has held it in 3 quarters since.
  • Ilex Capital Partners's Charles River Laboratories position peaked at $33.9M in Q1 2026.
  • 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Ilex Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.